Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Date:9/4/2007

a class of medicines that relaxes muscles in the bladder and prostate.

"This study provides important new data to guide initial therapy for men with symptomatic BPH," said Claus Roehrborn, M.D., Professor and Chairman, Department of Urology, UT Southwestern Medical Center at Dallas and CombAT principal investigator. "This is the first time we have seen a benefit for combination therapy over monotherapy during the first 12 months of treatment."

CombAT Two-Year Results

The findings reported today are intermediate results from a study that remains active. Researchers will issue a final report at the end of four years regarding the efficacy of AVODART, tamsulosin, and combination therapy in reducing the risk of symptomatic disease progression and the risk of urinary retention (AUR) and prostate surgery in men with moderate-to-severe enlarged prostate symptoms.

Poster presentation: "The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms and Qmax in men with BPH and prostatic enlargement"

According to this analysis, the two-year primary endpoint was achieved in the CombAT study. Symptom improvement was measured using the International Prostate Symptom Score (IPSS), a validated assessment questionnaire recommended by the American Urological Association (AUA). Over 24 months, AVODART and tamsulosin combination therapy provided a significantly greater (p < 0.001) improvement in symptoms (IPSS) from baseline (6.2 units) than either AVODART (4.9 units) or tamsulosin (4.3 units) treatment alone. In fact, the CombAT study demonstrated the benefit of combination therapy over both monotherapies in the first 12 months of treatment. With combination therapy, patients experienced continuous improvement of symptoms throughout the two years of the study.

Poster presentation: "Dutasteride provides greater improvement in symptoms and Qmax than tamsulosin in men with moderate-to-severe symptoms of BPH and prosta
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...-- CryoLife,Inc. (NYSE: CRY ),animplantablebiologi...ompany,announcedtodaythatitisscheduledtoparticipat...erenceatTheNewYorkPalaceHotelonDecember1,2009. ,...cerofCryoLife,Inc.,willprovideacorporateoverviewre...onandanswersessionat4:30p.m.EasternTime. ,, Cry...
(Date:11/23/2009)...rstCall/--WoundManagementTechnologies,Inc.,(OTCBul...medicalproducts,announcedthatithasfileditQ32009fin...tbusinessupdatetoillustratethedevelopmentsduringth...%to$102,926vs.Q32008salesof$77,084. , Shareho...008shareholderequityof$(321,257) , Totalasset...
(Date:11/23/2009)...stCall/--Pharmasset,Inc.(Nasdaq: VRUS )announcedto...(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcontinueforthere...trialofRG7128,afirst-in-classnucleosideanalogpolym...rus(HCV)infection.Thedecisionwasreachedafterasched...MC)ofallavailablesafetydatafromthefirstcohortofapp...
Breaking Medicine Technology:CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Scientists discover bioluminescent green bombers from the deep sea 9650 1Scientists discover bioluminescent green bombers from the deep sea 9650 2Scientists discover bioluminescent green bombers from the deep sea 9650 3Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 1Energy X Lip Balm Delivers Wake Up Call to Consumers 55004 2Recent Article Reveals Medical Ghostwriting Suppressed Links Between Synthetic Hormones and Breast Cancer 55002 1Recent Article Reveals Medical Ghostwriting Suppressed Links Between Synthetic Hormones and Breast Cancer 55002 2Recent Article Reveals Medical Ghostwriting Suppressed Links Between Synthetic Hormones and Breast Cancer 55002 3
...y led by,researchers at Joslin Diabetes Center has...ey factor in the cause of metabolic syndrome and i...tens of millions of,Americans at high risk of card...he February issue of Cell Metabolism,provide not o...urs, but,also pinpoint a target for treatment of t...
...ed Development for Chronic Pain and Non-Pain ...alif., Feb. 5 TorreyPines Therapeutics, Inc.,(Nas...ltiple dose clinical,trial of tezampanel, an antag...e receptors, show that the product candidate is sa...bjects., These Phase I results support the compan...
Other Medicine Technology:Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease 2Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 2Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 3Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 4
(Date:11/23/2009)...e the problem, researchers say , , MONDA...heir anger over unfair treatment at work could be ...s. , Men who consistently failed to express the...or supervisor were more than twice as likely to ha... who vented their anger, claims a report in the No...
(Date:11/23/2009)...swire/--TheAmericanSocietyofHematology(ASH)andScho...mediacompany,arelaunching"ExploretheMysteryofBlood...inthefieldsofscienceandmedicine,inadditiontoexposi...y. ,, "Manyhematologistsmayrememberwatchingacar...learningaboutbloodreallyfun,"statedNancyBerliner,M...
(Date:11/23/2009)...s enjoy a pay raise for a job well done. But in so... performance may actually backfire. , A new U...ngs for 25 medical groups across California improv...de pay-for-performance program in 2004 but not wh... , Reporting in the December edition of the Jou...
(Date:11/23/2009)...o reined in their hypertension, study found, , ... blood pressure is better controlled by doctor-pha... and pharmacists working alone, a new study shows....cations are intensified, dosages increased, medica..., a professor in the University of Iowa College of...
(Date:11/23/2009).../--Hazelden,theinternationallyrenownednonprofitadd...eamforitsnewrecoverycenterinNaples,Florida.Hazelde...rch2010,andwillinitiallyprovideaddictiontreatmentp...patientservices. ,, MichaelDemask,Ph.D.,willser...withBrendaIliff,M.A.,L.A.D.C.,asclinicaldirector,a...
Breaking Medicine News(10 mins):Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3Health News:Hazelden Names Leadership Team for New Recovery Center in Naples, Florida 2
...ay indicate more severe depression, rather than di... MONDAY, March 9 (HealthDay News) -- Women who use...or sudden cardiac death, although the exact nature..., "We suspect that their use is a marker for peopl...
...arch 9 Cardinal Justin Rigali, chairman of the U....o-Life Activities, today called President Obama,s ... sad victory of politics over science and ethics."... cell research. Cardinal Rigali also cited a Janua...
...alif., March 9 Natural Alternatives International,...tor and manufacturer of customized nutritional sup...science and marketing based distributor of raw mat...nt of the patented Carnosyn(R) beta-alanine to fur...
...s are available in condensed format at 15 location... gain new knowledge and improve skills , , UNIVER...ania now have even more options to receive valuabl...nclude timely, relevant topics, such as healthy li...
..., March 9 Medivation, Inc. (Nasdaq: MDVN ) ... and webcast with management to discuss fourth qua...de a general business update on Monday, March 16, ... 16, 2009. , , Interested parties may call 877-7...
...arch 9 In Kentucky, nearly one out of every two... but barely a quarter of the dentists accept the i...with few options when it comes to seeing a dentist...ted 10,000 toothbrushes and 30,000 tubes of toothp...
Other Medicine News:Health News:Antidepressant Use Tied to Cardiac Death in Women 2Health News:Antidepressant Use Tied to Cardiac Death in Women 3Health News:Executive Order on Embryonic Stem Cells 'A Sad Victory of Politics Over Science and Ethics,' Says Cardinal Rigali 2Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 2Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 3Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 4Health News:Penn State Expands Professional Development Program for School Nurses, Now in its Seventh Year 2Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: